Duke Alzheimer's Drug Gives Patients More Time With Loved Ones
A three-year study at Duke University shows that an Alzheimer's drug called lecanemab is helping patients slow disease progression and hold onto precious time. Nearly 80% of patients continued treatment for a full year, offering new hope for those in early stages of the disease.
